PD1-knockout chimeric antigen receptor T cell targeting CD20, preparation method and application thereof

A chimeric antigen receptor, CAR-CD20 technology, applied in the field of medical biology, can solve the problem that CART-CD19 can no longer exert anti-tumor effect

Inactive Publication Date: 2019-06-04
SHENZHEN BINDEBIOTECH CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since tumors of the same type often express different immune phenotypes, for example, when tumor cells escape CD19-negative, that is, there are tumor cells that do not express CD19, the CD19 target will fail, and CART-CD19 will no longer be able to function. Anti-tumor effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PD1-knockout chimeric antigen receptor T cell targeting CD20, preparation method and application thereof
  • PD1-knockout chimeric antigen receptor T cell targeting CD20, preparation method and application thereof
  • PD1-knockout chimeric antigen receptor T cell targeting CD20, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] A method for preparing CD20-targeted chimeric antigen receptor T cells knocked out of PD1, comprising the following steps:

[0092] (1) Prepare the gene sequence of chimeric antigen receptor CAR-CD20

[0093] Prepare the coding genes of signal peptide, single-chain antibody targeting CD20, CD8α hinge region, CD8 transmembrane region, 4-1BB signal region and CD3ζ signal region respectively, the coding gene of the signal peptide is shown in SEQ ID NO: 8 , the coding gene of the single-chain antibody targeting CD20 is shown in SEQ ID NO: 5, the coding gene of the CD8α hinge region is shown in SEQ ID NO: 10, and the coding gene of the CD8 transmembrane region is shown in SEQ ID NO: As shown in ID NO: 12, the coding gene of the 4-1BB signal region is shown in SEQ ID NO: 14, and the coding gene of the CD3ζ signal region is shown in SEQ ID NO: 16.

[0094] The genes encoding the above signal peptide, CD20-targeting single-chain antibody, CD8α hinge region, CD8 transmembrane r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a preparation method of a PD1-knockout chimeric antigen receptor T cell targeting CD20. The method comprises: linking an encoding gene of the chimeric antigen receptor CAR-CD20and targeting CD20 to a vector, and constructing the recombinant lentivirus, performing transfection on CD3 positive T lymphocytes, and performing knockout of the PD1 gene of the transfected T cells to obtain the PD1-knockout chimeric antigen receptor T cell targeting CD20. The knockout of the PD1 gene by the T cell is in favor of amplification of T cells in the patient, and avoids the escape of immunosurveillance of the tumor cells, and the T cell has the performance of killing CD20 positive tumor cells with high efficiency and specificity, which maintains the viability and lethality of the cells for a long time.

Description

technical field [0001] The invention relates to the field of medical biology, in particular to a chimeric antigen receptor T cell targeting CD20 knocked out of PD1 and its preparation method and application. Background technique [0002] CAR-T (Chimeric Antigen Receptor T Cell) technology is a new type of cell therapy, which is to reinfuse CAR-modified T cells into the human body, activate the autoimmune system, and kill tumor cells. The treatment of non-Hodgkin's lymphoma has a remarkable curative effect and is considered to be one of the most effective treatments for malignant tumors. [0003] At present, CAR-T technology has achieved remarkable results in CD19-positive blood tumors (such as B-cell lymphoma, acute and chronic B-lymphoblastic leukemia). However, since tumors of the same type often express different immune phenotypes, for example, when tumor cells escape CD19-negative, that is, there are tumor cells that do not express CD19, the CD19 target will fail, and C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/867C12N7/01C12N15/113C12N5/10A61P35/00
Inventor 曾滢张长风吴咏东
Owner SHENZHEN BINDEBIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap